Capital Fund Management S.A. Buys 107,587 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Capital Fund Management S.A. increased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 116.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 200,277 shares of the medical device company's stock after buying an additional 107,587 shares during the period. Capital Fund Management S.A. owned 0.30% of Tandem Diabetes Care worth $7,214,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. JPMorgan Chase & Co. raised its stake in Tandem Diabetes Care by 134.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock worth $8,379,000 after buying an additional 113,355 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after purchasing an additional 1,101 shares in the last quarter. US Bancorp DE grew its position in shares of Tandem Diabetes Care by 15.2% in the 4th quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock valued at $1,394,000 after purchasing an additional 5,108 shares during the period. KBC Group NV increased its stake in Tandem Diabetes Care by 41.5% during the 4th quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock worth $6,933,000 after purchasing an additional 56,461 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its stake in Tandem Diabetes Care by 22.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock worth $236,000 after purchasing an additional 1,184 shares in the last quarter.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

TNDM has been the subject of several research reports. Robert W. Baird lowered their price objective on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a research report on Thursday, February 27th. The Goldman Sachs Group cut their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Canaccord Genuity Group reiterated a "buy" rating and set a $63.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Barclays cut their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Finally, Mizuho began coverage on shares of Tandem Diabetes Care in a report on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price objective on the stock. Nine investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $43.88.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock traded down $0.40 during trading hours on Friday, hitting $16.86. The company had a trading volume of 1,132,393 shares, compared to its average volume of 1,502,106. Tandem Diabetes Care, Inc. has a one year low of $15.75 and a one year high of $53.69. The firm has a market cap of $1.12 billion, a PE ratio of -8.74 and a beta of 1.52. The firm has a 50-day moving average of $22.10 and a 200 day moving average of $30.28. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.